Overview
- On October 8–9, multiple outlets reported that Isomorphic is in early-stage talks to raise fresh capital at a valuation of at least $40 billion and possibly up to $50 billion, and sources say no deal has closed.
- Isomorphic was founded in 2021 as a DeepMind spinout and is led by Demis Hassabis with Alphabet remaining the majority owner after prior funding rounds.
- The company has raised about $2.7 billion in disclosed external funding so far, including a $600 million Series A in March 2025 and a $2.1 billion Series B in May 2026.
- Isomorphic’s platform, called the Isomorphic Drug Design Engine or IsoDDE, builds on DeepMind’s AlphaFold and the firm has partnerships with Eli Lilly, Novartis, and Johnson & Johnson that carry more than $3 billion in potential milestone payments tied to scientific progress.
- The reported valuation jump would far outstrip current market forecasts for the AI drug-discovery sector and puts focus on a near-term test of the company’s approach because Isomorphic has not yet dosed patients and says it plans first-in-human trials by the end of 2026.